Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy

Amid HHS upheaval, Bhattacharya takes the helm at NIH, Makary at FDA
Meanwhile, NASEM sounds “SOS” for health infrastructure

Conversation with The Cancer Letter

Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising record
Current record: $507,000. Proceeds to go to LLS as NIH funding is slashed

Guest Editorial

Rathmell: We must put the individual at the center of our approach to ending cancer

How City of Hope is using AI to improve surgical outcomes

In Brief

Alec Kimmelman announced as next CEO and Dean of NYU Langone Health

Don Dizon to join Tufts as system chief of hematology-oncology

Karen Pollok, Tim Lautenschlaeger, Jiang Bian named to leadership at IU Simon CCC

Less Radical, a podcast about Bernie Fisher, nominated for two Webby Awards

CRUK and partners pledge £5.5m funding for colorectal cancer research

University Hospitals Cleveland, Qure.ai collaborate on early lung cancer detection

Drugs & Targets

FDA approves durvalumab for muscle invasive bladder cancer

CHMP recommends approval of Calquence plus chemoimmunotherapy for first-line mantle cell lymphoma

CHMP recommends approval for Tevimbra as a first-line treatment for extensive-stage small cell lung cancer

Exact Sciences launches the Cologuard Plus test for colorectal cancer screening

FDA approves cabozantinib for patients 12 and up with pNET and epNET

FDA approves prostate cancer imaging agent Gozellix

In The Clinic

Survey reveals most Americans are uninformed about HPV
A vaccine can prevent cancer—most people don’t take it

Free Trials & Tribulations

The new therapeutic imperative in cancer management: Sequence, biosimulate, treat

Trials & Tribulations

LLS former CSO: Immunotherapy, precision medicine redefined blood cancer treatment

Trials & Tribulations

Physicians and biopharma should improve accessibility of cancer trials

Trials & Tribulations

From clinician scientist to nonprofit CEO

Latest Issue

Read the latest issue

DOWNLOAD THE PDF

NEWS ALERTS

Stay up to date on the latest news in oncology by joining our mailing list.

UPCOMING EVENTS

Apr 2025

Miami Leukemia Symposium

Cellicon Valley ’25: The Future of Cell and Gene Therapies

May 2025

NCCN Oncology Policy Summit: Primary Care and Oncology Collaboration to Improve Patient Outcomes

2025 AAADV Workshop

2025 ASCO Annual Meeting

View All Events

Conversations with The Cancer Letter

Jonathan Friedberg tells us how he built a cancer center in an underserved area of New York State

Shearwood McClelland III: “When you stand for something, you’re always going to be attacked.”

Brian Rivers: Celebrating Black history reinforces the dynamic culture of America
“It gives America, in part, its identity.”

RWD company documents baseline trends in women’s cancers before Trump’s policy changes

Contributors

W. Kimryn Rathmell, MD, PhD, MMHC

Rathmell: We must support our junior colleagues
“Empathy and listening is a key place to start”

Jedd D. Wolchok, MD, PhD

Weill Cancer Hub East to investigate connections between metabolism and anti-tumor immunity
Weill Cornell, Rockefeller, Princeton and the Ludwig Institute for Cancer Research showcase the power of collaboration

Edward S. Kim, MD, MBA

Building a nationally integrated cancer research and treatment network

Shannon McWeeney, PhD

Caught in the crossfire: The critical threats facing cancer centers, research, and patient care

Trending Stories

DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated
What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns”
Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy
In The Headlines: HHS shakeup threatens a legacy of medical breakthroughs
Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising record
Current record: $507,000. Proceeds to go to LLS as NIH funding is slashed
Amid HHS upheaval, Bhattacharya takes the helm at NIH, Makary at FDA
Meanwhile, NASEM sounds “SOS” for health infrastructure

Recent Issues

The Cancer Letter is an independent weekly news publication and the leading source for information on the issues that shape oncology.

Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy

Amid HHS upheaval, Bhattacharya takes the helm at NIH, Makary at FDA
Meanwhile, NASEM sounds “SOS” for health infrastructure

Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising record
Current record: $507,000. Proceeds to go to LLS as NIH funding is slashed

Rathmell: We must put the individual at the center of our approach to ending cancer

How City of Hope is using AI to improve surgical outcomes

Alec Kimmelman announced as next CEO and Dean of NYU Langone Health

Don Dizon to join Tufts as system chief of hematology-oncology

Karen Pollok, Tim Lautenschlaeger, Jiang Bian named to leadership at IU Simon CCC

Less Radical, a podcast about Bernie Fisher, nominated for two Webby Awards

CRUK and partners pledge £5.5m funding for colorectal cancer research

University Hospitals Cleveland, Qure.ai collaborate on early lung cancer detection

FDA approves durvalumab for muscle invasive bladder cancer

CHMP recommends approval of Calquence plus chemoimmunotherapy for first-line mantle cell lymphoma

CHMP recommends approval for Tevimbra as a first-line treatment for extensive-stage small cell lung cancer

Exact Sciences launches the Cologuard Plus test for colorectal cancer screening

FDA approves cabozantinib for patients 12 and up with pNET and epNET

FDA approves prostate cancer imaging agent Gozellix

Survey reveals most Americans are uninformed about HPV
A vaccine can prevent cancer—most people don’t take it

The new therapeutic imperative in cancer management: Sequence, biosimulate, treat

LLS former CSO: Immunotherapy, precision medicine redefined blood cancer treatment

Physicians and biopharma should improve accessibility of cancer trials

From clinician scientist to nonprofit CEO

Jonathan Friedberg tells us how he built a cancer center in an underserved area of New York State

Shearwood McClelland III: “When you stand for something, you’re always going to be attacked.”

Brian Rivers: Celebrating Black history reinforces the dynamic culture of America
“It gives America, in part, its identity.”

RWD company documents baseline trends in women’s cancers before Trump’s policy changes

W. Kimryn Rathmell, MD, PhD, MMHC

Jedd D. Wolchok, MD, PhD

Edward S. Kim, MD, MBA

Shannon McWeeney, PhD

Never miss an issue!

Login

Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy

Jonathan Friedberg tells us how he built a cancer center in an underserved area of New York State

Shearwood McClelland III: “When you stand for something, you’re always going to be attacked.”

Brian Rivers: Celebrating Black history reinforces the dynamic culture of America“It gives America, in part, its identity.”

RWD company documents baseline trends in women’s cancers before Trump’s policy changes

Never miss an issue!

Login

Brian Rivers: Celebrating Black history reinforces the dynamic culture of America
“It gives America, in part, its identity.”